RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus, 2015

Madhu, Sri Venkata; Saboo, Banshi; Makkar, Brij; Reddy, Gundam Chandrasekhara; Jana, Jayaprakashsai; Panda, Jayant K.; Singh, Rajesh; Setty, Narasimha; Rao, Paturi Vishnupriya; Chawla, Rajeev; Sahay, Rakesh; Aravind, S.R.; Banerjee, Subhadeep; Bajaj, Sarita; Kumar, Vasant; Panikar, Vijay

doi:10.1007/s13410-015-0450-9

Cited by 18 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Grading recommendations in accordance with the nature and relative complexities of barriers that need to be navigated for successful implementationd translatability scale (13)dis therefore advised. A good example is the IDF's global guideline (40), which was emulated by the Sri Lankan and Indian guidelines (41,42) where recommendations were divided into minimal, standard, and comprehensive care. The Belize guideline (43) also separated investigations into two categories: the required minimum and those to be carried out only if clinically indicated.…”

Section: Discussionmentioning

confidence: 99%

Gaps in Guidelines for the Management of Diabetes in Low- and Middle-Income Versus High-Income Countries—A Systematic Review

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Gaps in Guidelines for the Management of Diabetes in Low- and Middle-Income Versus High-Income Countries—A Systematic Review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…[10] SGLT2i are available in India but not in Pakistan and Sri Lanka, and the T2DM management strategy of these South Asian countries is shown in Table S1. [111213]…”

Section: Sodium–glucose Co-transporter Inhibitorsmentioning

confidence: 99%

Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement

Kalra

Ghosh

Aamir

et al. 2017

Indian J Endocr Metab

Self Cite

View full text Add to dashboard Cite

Diabetes prevalence shows a continuous increasing trend in South Asia. Although well-established treatment modalities exist for type 2 diabetes mellitus (T2DM) management, they are limited by their side effect profile. Sodium–glucose co-transporter 2 inhibitors (SGLT2i) with their novel insulin-independent renal action provide improved glycemic control, supplemented by reduction in weight and blood pressure, and cardiovascular safety. Based on the clinical outcomes with SGLT2i in patients with T2DM, treatment strategies that make a “good clinical sense” are desirable. Considering the peculiar lifestyle, body types, dietary patterns (long duration religious fasts), and the hot climate of the South Asian population, a unanimous decision was taken to design specific, customized guidelines for T2DM treatment strategies in these regions. The panel met for a discussion three times so as to get a consensus for the guidelines, and only unanimous consensus was included. After careful consideration of the quality and strength of the available evidence, the executive summary of this consensus statement was developed based on the American Association of Clinical Endocrinologists/American College of Endocrinology protocol.

show abstract

“…Both national and international guidelines support the use of SGLT2 inhibitors either as monotherapy or as add-on therapy for the management of T2DM. [2930313233] Recently, the National Institute for Health and Care Excellence guideline has approved the use of canagliflozin as monotherapy when diet and exercise do not provide adequate glycemic control and metformin was contraindicated or not tolerated or as add-on therapy with antihyperglycemic agents (AHAs), widening the available treatment options for practicing clinicians. [3435] Among the available SGLT2 inhibitors, canagliflozin is widely used as doses of 100 and 300 mg once daily (OD).…”

Section: Introductionmentioning

confidence: 99%

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

Kumar

Ghosh

Canovatchel

et al. 2017

Indian J Endocr Metab

View full text Add to dashboard Cite

Currently available antihyperglycemic agents, despite being effective, provide inadequate glycemic control and/or are associated with side effects or nonadherence. Canagliflozin, a widely used orally active inhibitor of sodium-glucose cotransporter 2 (SGLT2), is a new addition to the therapeutic armamentarium of glucose-lowering drugs. This review summarizes findings from different clinical and observational studies of canagliflozin 300 mg in patients with type 2 diabetes mellitus (T2DM). By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose, thereby increasing urinary glucose excretion in patients with T2DM. Canagliflozin 300 mg has been shown to be effective in lowering glycated hemoglobin, fasting plasma glucose, and postprandial glucose in patients with T2DM. Canagliflozin 300 mg also demonstrated significant reductions in body weight and blood pressure and has a low risk of causing hypoglycemia, when not used in conjunction with insulin and insulin secretagogues. Canagliflozin 300 mg was generally well tolerated in clinical studies. The most frequently reported adverse events include genital mycotic infections, urinary tract infections, osmotic diuresis, and volume depletion-related events.

show abstract

RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus, 2015

Cited by 18 publications

References 0 publications

Gaps in Guidelines for the Management of Diabetes in Low- and Middle-Income Versus High-Income Countries—A Systematic Review

Gaps in Guidelines for the Management of Diabetes in Low- and Middle-Income Versus High-Income Countries—A Systematic Review

Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus

Contact Info

Product

Resources

About